This message contains images. If you don't see images, click here to view.
Click
here to advertise in this news brief.
Advertisement
|
|
Advertisement
Advertisement
|
|
Advertisement
Cancer risk after ABO-incompatible living-donor kidney transplantation
Transplantation (login required)
Recipients of ABO-incompatible living-donor kidney transplants often undergo more intense immunosuppression than their ABO-compatible counterparts. It is unknown if this difference leads to higher cancer risk after transplantation. Single-center studies are too small and lack adequate duration of follow-up to answer this question.
Advertisement
Free UNOS webinar series on new living kidney donor policy requirements
AST
Oct. 2: HCC in Liver Transplantation: Appearances Are Everything - Defining Imaging Characteristics for HCC in Liver Transplantation
Nov. 6: OPTN Requirements for Living Kidney Donor Follow Up
CEPTC credit is available. All webinars are 2-3 p.m. EST. Click here for more information and to register for future webinars. For questions, contact Kim Johnson, MS, Instructional Innovations Coordinator, at (804) 782-4654 or kim.johnson@unos.org.
PRODUCT SHOWCASE
 |
|
The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
|
|
Now accepting applications for research grant funding
AST
The AST is now accepting applications for 2014 research grants. The deadline for complete application submission is Monday, Dec. 16. Learn more about available grants and application criteria here, or start your application today!
Wanted: Your nominations for the 2014 AST Board
AST
Dr. Roslyn Mannon, chair of the AST Governance Committee, invites AST members to submit nominations for qualified individuals to serve on the AST Board of Directors. Open positions include president-elect (one year term), treasurer (two year term), and three councilors-at-large (three year terms each). Read the official announcement here.
Heart transplantation for end-stage heart failure due to cardiac sarcoidosis
Transplantation Proceedings (login required)
Cardiac sarcoidosis with end-stage heart failure has a poor prognosis without transplantation. The rates of sarcoid recurrence and rejection are not well established after heart transplantation. In a recent study, a total of 19 heart transplant recipients with sarcoid of the explanted heart were compared with a contemporaneous control group of 1,050 heart transplant recipients without cardiac sarcoidosis.
Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation
Liver Transplantation (login required)
Preformed donor-specific human leukocyte antigen antibodies (DSAs) are considered a contraindication to the transplantation of most solid organs other than the liver. Conflicting data currently exist on the importance of preformed DSAs in rejection and patient survival after liver transplantation (LT). To evaluate preformed DSAs in LT, we retrospectively analyzed prospectively collected samples from all adult recipients of primary LT without another organ from Jan. 1, 2000 to May 31, 2009 with a pre-LT sample available.
|
Advertisement
|
 |
|
Astellas is entering its 20th year focusing on transplant immunology. Today we remain steadfast in our commitment to advancing the field. Tomorrow we will seek new possibilities to help improve the transplant experience. Together. Please visit astellas.us
|
|
Advertisement
|
 |
|
The University of Vermont/Fletcher Allen Health Care is seeking applications for a senior faculty member to join the Division of Nephrology. The candidate should be UNOS certified in kidney and pancreas transplants, experienced in educating nephrology fellows, growing transplant programs, and providing administrative leadership.
Apply Here
|
|
|
|
|
 |
|
|
The FlowSight offers high performance in a small package. Its innovative design increases signal and minimizes noise to provide unmatched fluorescence sensitivity. Twelve standard detection channels simultaneously produce brightfield, darkfield and up to ten channels of fluorescence imagery of every cell. More info
|
|
Effects of N-acetylcysteine on cytokines in non-acetaminophen acute liver failure: potential mechanism of improvement in transplant-free survival
Liver International (login required)
N-Acetylcysteine (NAC) improves transplant-free survival in patients with non-acetaminophen acute liver failure (ALF) when administered in early stages of hepatic encephalopathy. The mechanisms of this benefit are unknown.
Organ donation: Presumed consent to start in December 2015
BBC News
People in Wales will be presumed to have agreed for their organs to be donated after death from December 2015.
Wales will be the first U.K. nation to introduce a system where consent is assumed unless people have opted out. The legislation, described by ministers as the "most significant" the Welsh assembly had passed, recently received royal assent.
Currently, people across the U.K. join a voluntary scheme and carry a card if they wish to donate organs.
Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients
Transplant Infectious Disease (login required)
A recent study examined the relationship between voriconazole utilization and non-melanoma skin cancer (NMSC) development among adult lung and heart/lung transplant patients who were continuously enrolled in a large U.S. commercial health plan.
Missed last week's issue? See which articles your colleagues read most.
Systematic bias in surgeons' predictions of the donor-specific risk of liver transplant graft failure
Liver Transplantation (login required)
The decision to accept or decline a liver allograft for a patient on the transplant waiting list is complex. It has been hypothesized that surgeons are not accurate at predicting donor-specific risks. Surgeon members of the American Society of Transplant Surgeons were invited to complete a survey in which they predicted the three-year risk of graft failure for a 53-year-old man with alcoholic cirrhosis and a model for end-stage liver disease score of 21 with a liver from a 30-year-old local donor with traumatic brain death or a 64-year-old regional donor with brain death from a stroke. Complete responses were obtained from 201 surgeons, whose self-reported case volume represents the majority of liver transplants in the United States.
Will China's organ transplant reforms really work?
The Atlantic
The now oft-derided Chinese Red Cross once again found itself in hot water in July, when it was reported that some branches have asked organ transplant hospitals to pay 100,000 RMB (US $16,300) for each successful organ donation organized by them. In August, the People’s Daily reported that an organ donation coordinator for the Shannxi branch of the Red Cross threatened to take away a critically injured patient’s breathing machine if the family continued to refuse to donate his organs in the event of a cardiac death. The coordinator, Liu Linjuan, said to the family that if they were willing to donate, "we can give you 100,000 RMB. No more than that."
A two-year prospective study of bone health in children after renal transplantation employing two imaging techniques
Clinical Transplantation (login required)
The aim of this study was to prospectively and longitudinally evaluate bone properties with the use of two bone imaging techniques (dual energy X-ray absorptiometry [DXA], and quantitative ultraSonography [QUS]) in pediatric renal transplant recipients.
Granulocyte colony-stimulating factor therapy: Reduced incidence of acute rejection episodes, allograft vasculopathy in heart transplant recipients
Transplantation Proceedings (login required)
The potential effects of granulocyte colony-simulating factor (G- CSF) on the incidence of rejection and allograft vasculopathy in heart transplant recipients were evaluated in a recent study.
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
Mobile version
